BioDelivery Sciences International Inc (BDSI.OQ)
19 Dec 2014
|Market Cap (Mil.):||$669.79|
|Shares Outstanding (Mil.):||51.29|
July 7 - Endo International Plc and BioDelivery Sciences International Inc said their experimental pain drug was found effective in a second late-stage trial, taking the drug a step closer to a marketing approval.
July 7 - Endo International Plc and BioDelivery Sciences International Inc said their experimental pain drug was found effective in a late-stage trial.
|Kyowa Hakko Kirin Co Ltd (4151.T)||¥1,145||-23.00|
|Johnson & Johnson (JNJ.N)||$105.55||-1.26|
|Pfizer Inc. (PFE.N)||$31.94||-0.03|
|Teva Pharmaceutical Industries Limited (TEVA.TA)||22,190.00₪||+520.00|
|Covidien plc (COV.N)||$102.90||-0.32|
|Actavis Inc (WATS.O)||--||--|
|Wolters Kluwer (WLSNc.AS)||€24.86||+0.22|
|Orexo AB (ORX.ST)||132.25kr||+4.75|
|Paladin Labs Inc. (PLB.TO)||--||--|
|Insys Therapeutics Inc (INSY.OQ)||$45.34||-1.35|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Trading Report for (BDSI). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of BIODELIVERY SCIENCES INTL including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
"The Economy Matters" Report for BDSI: the economy's impact on BDSI's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.